Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biclonal and hypodiploid multiple myeloma.

L Smith, B Barlogie, R Alexanian

    The American Journal of Medicine
    |May 1, 1986
    PubMed
    Summary

    Low RNA content in multiple myeloma patients correlates with poor chemotherapy response and suggests a genetic basis for treatment resistance. This finding is crucial for understanding treatment outcomes in myeloma.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma.

    Leukemia·2018
    Same author

    Drug response prediction in high-risk multiple myeloma.

    Gene·2017
    Same author

    Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.

    Nature communications·2017
    Same author

    Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma.

    Leukemia·2017
    Same author

    NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma.

    Leukemia·2017
    Same author

    Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.

    Blood cancer journal·2017

    Area of Science:

    • Hematology
    • Oncology
    • Molecular Biology

    Background:

    • Multiple myeloma is a cancer of plasma cells.
    • Treatment resistance remains a significant challenge in managing multiple myeloma.
    • Understanding the genetic underpinnings of resistance is critical for improving patient outcomes.

    Purpose of the Study:

    • To investigate the relationship between plasma cell DNA/RNA content and chemotherapy response in multiple myeloma.
    • To identify potential genetic factors contributing to treatment resistance.

    Main Methods:

    • Flow cytometry was used to analyze DNA and RNA content in bone marrow plasma cells.
    • Acridine orange staining was employed for cell analysis.
    • Seventy-two untreated multiple myeloma patients were included in the study.

    Main Results:

    • Biclonal or hypodiploid DNA stemlines were observed in 10 patients.
    • Nine of these patients with abnormal DNA stemlines also exhibited low RNA content and did not respond to chemotherapy.
    • Biclonal tumors showed altered protein expression during chemotherapy, indicating differential clone response.

    Conclusions:

    • Low RNA content in plasma cells is associated with resistance to chemotherapy in multiple myeloma.
    • The presence of biclonal or hypodiploid DNA stemlines may indicate a genetic basis for this resistance.
    • These findings highlight the potential of DNA/RNA content as a biomarker for predicting treatment response.

    Related Experiment Videos